![Cancers | Free Full-Text | Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors Cancers | Free Full-Text | Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors](https://pub.mdpi-res.com/cancers/cancers-13-00287/article_deploy/html/images/cancers-13-00287-g001.png?1611289275)
Cancers | Free Full-Text | Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors
![Indian cancer doctors talk about the miracle drug 'Dostarlimab' trial that completely removed cancer: Do we have a cancer cure in sight? - Times of India Indian cancer doctors talk about the miracle drug 'Dostarlimab' trial that completely removed cancer: Do we have a cancer cure in sight? - Times of India](https://static.toiimg.com/thumb/msid-92180684,width-1280,resizemode-4/92180684.jpg)
Indian cancer doctors talk about the miracle drug 'Dostarlimab' trial that completely removed cancer: Do we have a cancer cure in sight? - Times of India
![Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial - The Lancet Oncology Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial - The Lancet Oncology](https://www.thelancet.com/cms/asset/b00f518e-35e4-480a-bbc3-65357e7af1ec/gr1.jpg)
Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial - The Lancet Oncology
![Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6–17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial - The Lancet Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6–17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial - The Lancet](https://www.thelancet.com/cms/attachment/011535c8-82ac-4b87-89a7-dcb43a5a808a/gr1.gif)
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6–17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial - The Lancet
![Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials | Nature Medicine Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials | Nature Medicine](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-02103-8/MediaObjects/41591_2022_2103_Fig1_HTML.png)
Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials | Nature Medicine
![High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial - The Lancet Oncology High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/dbec891b-f83b-4e40-8287-f397533b9221/gr1.gif)
High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial - The Lancet Oncology
![Pictorial French Follies 3/1930-2nd issue-spicy stories, pix-art-pulp-VG/FN | Comic Collectibles - Magazines / HipComic Pictorial French Follies 3/1930-2nd issue-spicy stories, pix-art-pulp-VG/FN | Comic Collectibles - Magazines / HipComic](https://storage.googleapis.com/hipcomic/p/1f62e6411b3213936b0ed47c5ed1f002-800.jpg)
Pictorial French Follies 3/1930-2nd issue-spicy stories, pix-art-pulp-VG/FN | Comic Collectibles - Magazines / HipComic
![Aleix Prat #PrecisionOncology on Twitter: "Dr. Fatima Cardoso brings to imporant topics to discuss one day: 1) what should be the primary endpoint in advanced TNBC? OS? 2) implications for patients and Aleix Prat #PrecisionOncology on Twitter: "Dr. Fatima Cardoso brings to imporant topics to discuss one day: 1) what should be the primary endpoint in advanced TNBC? OS? 2) implications for patients and](https://pbs.twimg.com/media/EiSfbmDXkAAtI0-.jpg:large)
Aleix Prat #PrecisionOncology on Twitter: "Dr. Fatima Cardoso brings to imporant topics to discuss one day: 1) what should be the primary endpoint in advanced TNBC? OS? 2) implications for patients and
![Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial - The Lancet Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial - The Lancet](https://www.thelancet.com/cms/attachment/0d3d5972-77c1-4161-bbf6-a21c4ab51b4a/gr1.gif)
Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial - The Lancet
![Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial | Nature Medicine Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial | Nature Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-022-01829-9/MediaObjects/41591_2022_1829_Fig1_HTML.png)
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial | Nature Medicine
![Interim results of the safety and immune-efficacy of 1 versus 2 doses of COVID-19 vaccine BNT162b2 for cancer patients in the context of the UK vaccine priority guidelines | medRxiv Interim results of the safety and immune-efficacy of 1 versus 2 doses of COVID-19 vaccine BNT162b2 for cancer patients in the context of the UK vaccine priority guidelines | medRxiv](https://www.medrxiv.org/content/medrxiv/early/2021/03/17/2021.03.17.21253131/F1.large.jpg)